Congenital Adrenal Hyperplasia — a common adrenal enzyme deficiency where the causative gene sits adjacent to a nearly identical pseudogene, making accurate molecular diagnosis one of the most technically demanding in clinical genetics.
Whole genome sequencing resolves the CYP21A2/CYP21A1P pseudogene region with the allelic resolution needed to distinguish pathogenic variants from benign pseudogene sequences — the core diagnostic challenge in CAH.
Congenital Adrenal Hyperplasia
Congenital adrenal hyperplasia (CAH) is a group of autosomal recessive disorders of adrenal steroidogenesis. The most common form — 21-hydroxylase deficiency — accounts for over 90% of cases and is caused by pathogenic variants in the CYP21A2 gene (encoding steroid 21-hydroxylase) on chromosome 6p21.33. 21-hydroxylase is essential for cortisol and aldosterone synthesis; its deficiency leads to ACTH-driven adrenal hyperplasia, androgen excess, and variable cortisol and mineralocorticoid deficiency. CAH affects approximately 1 in 14,000 to 1 in 18,000 newborns worldwide for classic forms, with much higher rates in genetically isolated populations.
CAH presents as a clinical spectrum: the severe classic salt-wasting form causes neonatal adrenal crisis and virilization of 46,XX infants (ambiguous genitalia); the classic simple virilizing form causes virilization with preserved mineralocorticoid function; and the non-classic (late-onset) form presents with signs of androgen excess in adolescence or adulthood — acne, hirsutism, menstrual irregularity, and infertility. Non-classic CAH has a carrier frequency of approximately 1 in 40 in Ashkenazi Jewish populations and 1 in 60-70 in the general European population. Genotype correlates broadly with phenotype: null variants (deletions, nonsense, frameshift) cause classic salt-wasting; severe missense variants cause simple virilizing; and milder missense variants (particularly p.Val282Leu) cause non-classic CAH.
The primary molecular diagnostic challenge in CAH is the genomic architecture of the CYP21A2 locus. The active CYP21A2 gene is situated immediately adjacent to an inactive pseudogene, CYP21A1P, which shares approximately 98% sequence identity at the nucleotide level. This high homology causes frequent gene conversion events — transfer of pseudogene sequences into the active CYP21A2 copy — and recurrent large deletions and duplications mediated by recombination between the two highly similar sequences. Standard sequencing approaches that do not specifically address this region can attribute pseudogene variants to the active gene (false positives) or miss large rearrangements entirely, leading to diagnostic errors.
21-hydroxylase deficiency accounts for >90% of CAH. Rarer forms — 11-beta-hydroxylase deficiency (CYP11B1), 17-alpha-hydroxylase deficiency (CYP17A1), 3-beta-HSD deficiency (HSD3B2) — each have distinct biochemical signatures and require specific gene evaluation.
The CYP21A2/CYP21A1P pseudogene structure makes this one of the most technically challenging loci in clinical genetics. Standard CAH panels miss gene conversion events and complex rearrangements that explain genotype-phenotype mismatches.
Standard sequencing cannot reliably distinguish CYP21A2 from its near-identical pseudogene
Short-read sequencing of the CYP21A2 locus using standard panel approaches is prone to two types of error: pseudogene sequences mapping to the active CYP21A2 gene (creating false positive variants) and true CYP21A2 variants being attributed to the pseudogene (false negatives). The 98% sequence identity between CYP21A2 and CYP21A1P means that short sequencing reads cannot consistently be assigned to the correct gene copy. Long-read sequencing approaches — increasingly incorporated into whole genome sequencing pipelines for complex loci — can resolve the CYP21A2/CYP21A1P haplotype structure with the allelic resolution that standard short-read panels cannot provide. This technical distinction is clinically critical: a diagnostic error in CAH can lead to either unnecessary treatment or missed diagnosis in a potentially life-threatening condition.
Complete CYP21A2 genotyping determines newborn treatment urgency and guides carrier testing in affected families
In newborn screening programs that detect elevated 17-hydroxyprogesterone, confirmatory CYP21A2 genotyping distinguishes classic salt-wasting CAH (requiring immediate salt supplementation and steroid therapy to prevent adrenal crisis) from simple virilizing or non-classic forms. The specific genotype — null allele compound heterozygous versus two mild alleles — determines both the urgency of treatment initiation and the predicted clinical trajectory. In known CAH families, prenatal diagnosis by chorionic villus sampling with complete CYP21A2 genotyping enables consideration of prenatal dexamethasone treatment in 46,XX fetuses before virilization occurs — a time-sensitive intervention that requires definitive genotyping early in the first trimester.
Your full DNA (not just a part of it)
Traditional genetic testing looks at narrow sets of genes, missing most parts of your genome. We sequence your full genome — every gene and every region between genes.
Comprehensive insights and specialized reports
Easy to read and with answers you and your doctor can act on. Not a file to interpret — 200+ clinical reports, organized by category.
Your test becomes more valuable every year
Your DNA does not change, but genome science is accelerating. Every month, new variant-disease associations are discovered. We validate these findings and update your reports automatically. Your test becomes more valuable every year.
The results doctors bring to their hardest cases.
Forty years of uncertainty. One test.
A patient had spent decades in the UK healthcare system without a diagnosis. Dante data, accepted by NHS clinical teams at Queen Elizabeth University Hospital Glasgow, identified Noonan Syndrome and a RUNX1 leukemia-associated variant that had gone undetected. After 40 years, they finally had an answer.
A complete read delivers a complete picture.
A patient came to Dante to investigate periodic paralysis. Reading the complete genome identified a concurrent hereditary cardiac finding — Brugada syndrome — that their doctor confirmed with an ECG. The result also explained a family member's unresolved cardiac history. One test. Every answer in it.
Sequenced in 2019. The data worked in 2021.
Jennifer sequenced her genome with Dante two years before her breast cancer diagnosis. When treatment began, Dante's pharmacogenomics data showed her prescribed chemotherapy would cause serious adverse effects. Her doctor selected an alternative — and she started effective treatment from day one.
Every genetic question deserves a complete answer.
Whether you are searching for answers today or protecting your health for tomorrow, a complete read of your entire genome is the only place to start.
It runs in your family. Now you can know if it runs in your genes.
Your genome contains inherited variants associated with medical conditions like cardiac, cancer, and neurological. We read all of them — with the clinical depth to give the result meaning.
Learn more →When traditional lab tests say you're fine. And you know you're not.
Standard diagnostic tests check for a pre-selected set of answers. We sequence your full DNA — including parts that no test was designed to check. If the answer is in your genome, we will help you find it.
Learn more →Your diagnosis may be right. Your treatment plan may be incomplete.
Your genes determine which treatments are most likely to work — and which are not. We give your doctor the tools and insights to inform your treatment plan.
Learn more →You want to know before something forces the question.
Some people don't wait for a diagnosis or a family history to act. Whole genome sequencing gives you the complete genetic picture now — so you and your doctor can make informed decisions before anything becomes urgent.
Learn more →You already took a DNA test. Here's what it couldn't tell you.
Most consumer DNA tests read less than 0.1% of your genome. We read all of it.
Learn more →Clinical-grade results. Chosen by individuals, trusted by doctors for their most complex cases.
Dante Genome Test helped specialists at a UK national acute hospital in the identification of Noonan Syndrome and a rare leukemia-associated genetic variant that had gone undetected. That result changed the medical care of the patient.
Accredited by & published in
Common questions about whole genome sequencing.
What is the difference between whole genome sequencing and a targeted genetic test?
Targeted genetic tests — including standard hereditary cancer panels — read a pre-defined list of known variants in a specific set of genes. They are designed to find what they already know to look for. Whole genome sequencing reads your entire genome: all 6 billion base pairs, every gene, every region between genes. A Mayo Clinic study published in JAMA Oncology found that standard testing guidelines missed more than half of patients with inherited cancer mutations. Genome Test does not have a fixed list.
What will I receive when my results are ready?
Your Dante Genome delivers 200+ physician-ready reports organized by clinical category — hereditary cancer, cardiac conditions, rare diseases, pharmacogenomics, carrier status, and more. Reports are delivered to your secure Genome Manager and are formatted for direct clinical use. Your genome data is permanently retained and re-analyzed automatically as science advances.
What happens if a clinically significant variant is found?
If a pathogenic or likely-pathogenic variant is identified, it will be clearly flagged in your physician-ready report with clinical context, published evidence, and recommended next steps. We recommend sharing any clinically significant finding with your physician or a genetic counselor, who can guide decisions about surveillance, risk reduction, or cascade testing for family members.
How is this different from a consumer DNA test like 23andMe or AncestryDNA?
Consumer DNA tests use genotyping chips that read less than 0.1% of your genome — a tiny pre-selected set of common variants. They are optimized for ancestry and population-level traits, not clinical genetic findings. The Dante Genome Test sequences 100% of your genome at 30X coverage, the same standard used in clinical diagnostic settings. The two tests are not comparable in scope, methodology, or clinical utility.
How long does it take to get results, and how are they delivered?
Your collection kit ships within 48 hours of ordering. Once your sample arrives at our CLIA-certified laboratory, sequencing and analysis takes 6–8 weeks. Results are delivered securely to your Genome Manager, where you can access your reports, share them with your physician, and receive automatic updates as new findings are validated against your genome.
We work with patient advocacy groups worldwide.
Dante Labs works with patient advocacy groups of any size — for Congenital Adrenal Hyperplasia and other conditions, rare and common. We support groups in any country, including virtual patient advocacy groups.
We can provide customized reports, group discounts, and packages tailored for your members. Please reach out using the form and we'll be in touch within two business days.
- Custom genomic reports for your members
- Group discounts and tailored packages
- Any country — including virtual groups
- Rare and common conditions covered
Message received.
We'll be in touch within 2 business days. To follow up directly: hello@dantelabs.com
One test.
A lifetime of answers.
One kit, sent to your home. Your entire genome sequenced at the clinical standard used for diagnostic decisions. 200+ physician-ready reports delivered to your Genome Manager in 6–8 weeks — permanent and updated as science advances.
Ships within 48 hours · Results in 6–8 weeks
